Gilead CV Therapeutics

Gilead Sciences Inc. headquarters in Foster City, Calif., is seen Thursday, March 12, 2009. Biotechnology company Gilead Sciences Inc. said Thursday it will buy CV Therapeutics for about $1.4 billion as a wave of consolidation in the drug industry continues. (AP Photo/Paul Sakuma)

Leave a Comment